Calithera Biosciences Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Calithera Biosciences Inc are displayed. Scroll down to the end of this webpage for potential risks for Calithera Biosciences Inc based on industry, location and size. This Disclosure rating covers seventeen United Nations SDGs including: 'No Poverty', 'Climate Action' and 'Life below Water'.
Calithera Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.7, social score of 3.2 and governance score of 4.0.
3.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1234 | Quanterix Corp | 3.4 | Medium |
1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
1253 | Calithera Biosciences Inc | 3.3 | Medium |
1253 | Cara Therapeutics Inc | 3.3 | Medium |
1253 | Celcuity Inc | 3.3 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Calithera Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Does Calithera Biosciences Inc disclose current and historical energy intensity?
Does Calithera Biosciences Inc report the average age of the workforce?
Does Calithera Biosciences Inc reference operational or capital allocation in relation to climate change?
Does Calithera Biosciences Inc disclose its ethnicity pay gap?
Does Calithera Biosciences Inc disclose cybersecurity risks?
Does Calithera Biosciences Inc offer flexible work?
Does Calithera Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Calithera Biosciences Inc disclose the number of employees in R&D functions?
Does Calithera Biosciences Inc conduct supply chain audits?
Does Calithera Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Calithera Biosciences Inc conduct 360 degree staff reviews?
Does Calithera Biosciences Inc disclose the individual responsible for D&I?
Does Calithera Biosciences Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Calithera Biosciences Inc disclose current and / or historical scope 2 emissions?
Does Calithera Biosciences Inc disclose water use targets?
Does Calithera Biosciences Inc have careers partnerships with academic institutions?
Did Calithera Biosciences Inc have a product recall in the last two years?
Does Calithera Biosciences Inc disclose incidents of discrimination?
Does Calithera Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Has Calithera Biosciences Inc issued a profit warning in the past 24 months?
Does Calithera Biosciences Inc disclose parental leave metrics?
Does Calithera Biosciences Inc disclose climate scenario or pathway analysis?
Does Calithera Biosciences Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Calithera Biosciences Inc disclose the pay ratio of women to men?
Does Calithera Biosciences Inc support suppliers with sustainability related research and development?
Does Calithera Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Calithera Biosciences Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Calithera Biosciences Inc involved in embryonic stem cell research?
Does Calithera Biosciences Inc disclose GHG and Air Emissions intensity?
Does Calithera Biosciences Inc disclose its waste policy?
Does Calithera Biosciences Inc report according to TCFD requirements?
Does Calithera Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Calithera Biosciences Inc disclose energy use targets?
Does Calithera Biosciences Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Calithera Biosciences Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Calithera Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.